Navigation Links
Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
Date:2/19/2009

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it completed its previously announced private placement of approximately 12 million shares of the Company's common stock at a price of $7.13 per share and five-year warrants to purchase up to approximately 6 million additional shares of the Company's common stock, exercisable in cash or by net exercise at a price of $7.84 per share, for aggregate gross proceeds of approximately $86.6 million. The price paid for the common stock is equal to the consolidated closing bid price on the Nasdaq Global Market on the day of pricing, February 13, 2009.

The financing was led by Venrock with participation by Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital and T. Rowe Price Associates.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Abou
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 03, 2014 Recently, Top ... hosting companies and announced that JustHost ( http://www.justhost.com/track/seohosts ... the webmasters. , “The hosting suppliers we recommend ... their competitors on hosting features, uptime and server ... 10 Best SEO Hosting says. “We believe that ...
(Date:9/2/2014)... 02, 2014 The use of Xarelto ... is growing at a rapid pace, even as ... courts around the U.S., Bernstein Liebhard LLP reports. According ... Medicine, within a year of its 2011 launch, patients ... warfarin, a blood thinner that has been in use ...
(Date:9/2/2014)... breast cancer in California, the percentage undergoing a double ... procedure was not associated with a lower risk of ... study in the September 3 issue of JAMA ... removal of one breast was associated with a higher ... the study. , Randomized trials have demonstrated similar survival ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey Bar and Grill ... Cord Injury Awareness Month featuring full band performances by Zane ... Automotive will be there hosting a Hot Rod, Rat Rod, ... The car show is Pre 1964 only, with a $50.00 ... There will be trophies for top 3 and best of ...
(Date:9/2/2014)... supplements did not reduce delirium in seniors who had ... Many older hospital patients experience the sudden, severe confusion ... sleep-wake cycle. A lack of the hormone melatonin may ... has been little research into whether melatonin supplements would ... average age 84, who had hip fracture surgery. About ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... HEIGHTS, N.J., May 2 Authentidate,Holding Corp. (Nasdaq: ... workflow,management software and web-based services, today announced the ... on Friday, May 2,2008, at the Grand Hyatt ... election of the following individuals to,serve on Authentidate,s ...
... Inc.,(Nasdaq: OSTE ) announces today that on April ... response to its notification to Nasdaq that,Robert W. Gunn, ... of,Directors, Audit and Compensation Committees, passed away unexpectedly on,April ... independent directors,serving on its Audit Committee and is not ...
... ATLANTA, May 2 Now in its 11th year ... cancer research, Georgia Power,s Run for,the Reason relay team ... and support the American Cancer Society. This year,s relay ... Georgia Power president and,CEO who passed away from cancer ...
... On the eve of the British Columbia inquiry into the ... CMAJ (Canadian Medical Association Journal) finds that in some cases, ... evidence is contrary to current views that stun guns only ... the pulses generated by stun guns are designed to incapacitate ...
... Properties, Inc.,s (NYSE: NHP ) Board of Directors declared ... that will be paid on,June 6, 2008 to shareholders of ... of Directors declared cash dividends of,$1.9375 per share on its ... be paid on June 30, 2008 to stockholders of,record on ...
... 2 Hill-Rom Holdings,Inc., (NYSE: HRC ) invites ... president and chief executive officer, Hill-Rom. He will be,speaking ... Las Vegas on,Thursday, May 15, 2008 at 9:10 a.m. ... listen to the live presentation via the internet,link at ...
Cached Medicine News:Health News:Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders 2Health News:Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders 3Health News:Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter 2Health News:Relay Team Runs to Raise Funds for the American Cancer Society 2Health News:Evidence that stun guns may stimulate the heart 2Health News:NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Depomed, ... it intends to offer, subject to market and other ... Notes due 2021 (the "Notes"). Depomed, Inc. ("Depomed") expects ... option to purchase up to an additional $34.5 million ... Co. LLC and RBC Capital Markets, LLC will act ...
(Date:9/2/2014)...  XBiotech announced today interim results from its ... US for its anti-cancer agent Xilonix™. ... being evaluated in advanced colorectal cancer patients where ... endpoint of the study is overall survival, comparing ... population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... September 2, 2014 According ... Market Research "Latin America Home Healthcare Market (By ... Healthcare Devices, Mobility Assist Devices and Medical Supplies; ... Infusion Therapy and Unskilled Home Healthcare Services) - ... 2014 - 2020" the Latin American Home Healthcare ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6
... , , SALT LAKE CITY , ... Heart Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory ...  the Company  received a NASDAQ Staff Deficiency Letter indicating that ... This Rule requires the Company to have at least three ...
... , BOSTON , Feb 5 ... to announce the Company has signed an agreement with Expert ... Company,s ISO 13485 quality management system (QMS) initiative. Expert Resource ... Endoscopy to create a quality management system that meets the ...
Cached Medicine Technology:NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: